- Home
- ANTX vs CURX Comparison
ANTX vs CURX Comparison
Compare ANTX & CURX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANTX
- CURX
- Stock Information
- Founded
- ANTX 2017
- CURX 2018
- Country
- ANTX United States
- CURX United States
- Employees
- ANTX N/A
- CURX N/A
- Industry
- ANTX Biotechnology: Pharmaceutical Preparations
- CURX Biotechnology: Pharmaceutical Preparations
- Sector
- ANTX Health Care
- CURX Health Care
- Exchange
- ANTX Nasdaq
- CURX Nasdaq
- Market Cap
- ANTX 34.4M
- CURX 29.7M
- IPO Year
- ANTX 2022
- CURX 2025
- Fundamental
- Price
- ANTX $1.12
- CURX $0.59
- Analyst Decision
- ANTX Buy
- CURX
- Analyst Count
- ANTX 2
- CURX 0
- Target Price
- ANTX $2.00
- CURX N/A
- AVG Volume (30 Days)
- ANTX 66.7K
- CURX 2.7M
- Earning Date
- ANTX 11-12-2025
- CURX 09-09-2025
- Dividend Yield
- ANTX N/A
- CURX N/A
- EPS Growth
- ANTX N/A
- CURX N/A
- EPS
- ANTX N/A
- CURX N/A
- Revenue
- ANTX N/A
- CURX N/A
- Revenue This Year
- ANTX N/A
- CURX N/A
- Revenue Next Year
- ANTX N/A
- CURX N/A
- P/E Ratio
- ANTX N/A
- CURX N/A
- Revenue Growth
- ANTX N/A
- CURX N/A
- 52 Week Low
- ANTX $0.98
- CURX $3.61
- 52 Week High
- ANTX $1.68
- CURX $8.60
- Technical
- Relative Strength Index (RSI)
- ANTX 38.88
- CURX N/A
- Support Level
- ANTX $1.12
- CURX N/A
- Resistance Level
- ANTX $1.24
- CURX N/A
- Average True Range (ATR)
- ANTX 0.07
- CURX 0.00
- MACD
- ANTX -0.01
- CURX 0.00
- Stochastic Oscillator
- ANTX 4.03
- CURX 0.00
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.
About CURX Curanex Pharmaceuticals Inc Common Stock
Curanex Pharmaceuticals Inc is engaged in discovering, developing, and commercializing botanical drugs for treating unmet medical needs in patients with inflammatory disease. Its compound, Phyto-N, is in preclinical research for six indications: ulcerative colitis, atopic dermatitis, COVID-19, type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) and gout.